{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f37d6aa67ac646ae82de3e520ecbfee0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "VBox(children=(HTML(value='<center> <img\\nsrc=https://huggingface.co/front/assets/huggingface_logo-noborder.sv…"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from huggingface_hub import login, notebook_login\n",
    "from langchain_huggingface import HuggingFacePipeline\n",
    "from transformers import AutoModelForCausalLM, AutoTokenizer, GenerationConfig, pipeline, BitsAndBytesConfig, AutoConfig\n",
    "import torch\n",
    "from textwrap import fill\n",
    "from langchain.prompts import PromptTemplate\n",
    "import locale\n",
    "from langchain.document_loaders import UnstructuredURLLoader\n",
    "from langchain.vectorstores.utils import filter_complex_metadata\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chains import RetrievalQA\n",
    "\n",
    "locale.getpreferredencoding = lambda: \"UTF-8\"\n",
    "\n",
    "notebook_login()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e7dd73ab1f1448999fecc4fd7ced1101",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/4 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "model_name = \"meta-llama/Meta-Llama-3.1-8B-Instruct\" \n",
    "\n",
    "quantization_config = BitsAndBytesConfig()\n",
    "\n",
    "model = AutoModelForCausalLM.from_pretrained(model_name,\n",
    "                                             device_map=\"cuda\",\n",
    "                                             quantization_config=quantization_config,\n",
    "                                             trust_remote_code=True)\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name, use_fast=True)\n",
    "\n",
    "gen_cfg = GenerationConfig.from_pretrained(model_name)\n",
    "gen_cfg.max_new_tokens=512\n",
    "gen_cfg.temperature=0.0000001 \n",
    "gen_cfg.return_full_text=True\n",
    "gen_cfg.do_sample=True\n",
    "gen_cfg.repetition_penalty=1.11\n",
    "\n",
    "pipe=pipeline(\n",
    "    task=\"text-generation\",\n",
    "    model=model,\n",
    "    tokenizer=tokenizer,\n",
    "    generation_config=gen_cfg\n",
    ")\n",
    "\n",
    "llm = HuggingFacePipeline(pipeline=pipe)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt_template_llama3 = \"\"\"\n",
    "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n",
    "\n",
    "Use the following context to report key figures and datapoints that would be of use for other applications. Do this in a concise manner, focusing on the most important figures and datapoints.\n",
    "Then answer these three questions in a concise manner:\n",
    "\n",
    "1) What are the key takeaways from the context?\n",
    "2) What key figures should focused on and what could be potentially drawn from them?\n",
    "3) What are steps for further analysis?\n",
    "\n",
    "Make sure to include specific details in your answers.\n",
    "\n",
    "{context}<|eot_id|><|start_header_id|>assistant<|end_header_id|>\n",
    "\"\"\"\n",
    "\n",
    "prompt_template = prompt_template_llama3\n",
    "\n",
    "prompt = PromptTemplate(\n",
    "    input_variables=[\"context\"],\n",
    "    template=prompt_template,\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading raw document...statements/REGN_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/SCHW_8-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/AMZN_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/V_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/DUK_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/JNJ_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/CSCO_8-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/MDLZ_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/ABBV_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/TMUS_8-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/MSFT_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/AMGN_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/NEE_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/VZ_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/LLY_8-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/NVDA_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/AAPL_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/JPM_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/INTC_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/T_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/CAT_8-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/MS_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/ADBE_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/SO_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/BIIB_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/F_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/BLK_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/AXP_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/C_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/ORCL_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/GS_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/GOOGL_8-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/CL_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/BA_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/BAC_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/KO_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/UL_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/HSY_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/MMM_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/MRK_8-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/PFE_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/KMB_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/GM_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/GILD_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/BMY_10-Q.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/PG_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/META_14-A.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/PEP_8-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/TSLA_10-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/GIS_8-K.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/K_S-1.md\n",
      "Splitting text...\n",
      "Loading raw document...statements/WFC_8-K.md\n",
      "Splitting text...\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "4528"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain.document_loaders import UnstructuredMarkdownLoader\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "\n",
    "import os\n",
    "\n",
    "# get all .md files in the statements/ directory\n",
    "md_files = [os.path.join('statements', fn) for fn in os.listdir('statements') if fn.endswith('.md')]\n",
    "\n",
    "# create loaders for each .md file\n",
    "loaders = [UnstructuredMarkdownLoader(fn) for fn in md_files]\n",
    "\n",
    "chunked_md_doc = []\n",
    "\n",
    "for loader in loaders:\n",
    "    print(\"Loading raw document...\" + loader.file_path)\n",
    "    md_doc = loader.load()\n",
    "    updated_md_doc = filter_complex_metadata(md_doc)\n",
    "    print(\"Splitting text...\")\n",
    "    text_splitter = RecursiveCharacterTextSplitter(chunk_size=1024, chunk_overlap=256)\n",
    "    documents = text_splitter.split_documents(updated_md_doc)\n",
    "    chunked_md_doc.extend(documents)\n",
    "\n",
    "len(chunked_md_doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/liam/VSCodeProjects/EDGAR-RAG/env/lib/python3.10/site-packages/langchain_core/_api/deprecation.py:139: LangChainDeprecationWarning: The class `HuggingFaceEmbeddings` was deprecated in LangChain 0.2.2 and will be removed in 0.3.0. An updated version of the class exists in the langchain-huggingface package and should be used instead. To use it run `pip install -U langchain-huggingface` and import as `from langchain_huggingface import HuggingFaceEmbeddings`.\n",
      "  warn_deprecated(\n"
     ]
    }
   ],
   "source": [
    "embedding_model_name = \"sentence-transformers/all-mpnet-base-v2\"\n",
    "model_kwargs = {\"device\": \"cuda\"}\n",
    "\n",
    "embeddings = HuggingFaceEmbeddings(\n",
    "    model_name=embedding_model_name,\n",
    "    model_kwargs=model_kwargs\n",
    ")\n",
    "\n",
    "vector_store = FAISS.from_documents(chunked_md_doc, embeddings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading raw document... testing/0.md\n",
      "Performing similarity search for document: testing/0.md\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:128001 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:128001 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Response for document testing/0.md:\n",
      "\n",
      "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n",
      "\n",
      "Use the following context to report key figures and datapoints that would be of use for other applications. Do this in a concise manner, focusing on the most important figures and datapoints.\n",
      "Then answer these three questions in a concise manner:\n",
      "\n",
      "1) What are the key takeaways from the context?\n",
      "2) What key figures should focused on and what could be potentially drawn from them?\n",
      "3) What are steps for further analysis?\n",
      "\n",
      "Make sure to include specific details in your answers.\n",
      "\n",
      "0 1. Name and Address of Reporting Person*QUAN NANCY (Last) (First) (Middle) THE COCA-COLA COMPANY ONE COCA-COLA PLAZA (Street) ATLANTA GA 30313 (City) (State) (Zip) QUAN NANCY (Last) (First) (Middle) THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol COCA COLA CO [ KO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Executive Vice President Director 10% Owner X Officer (give title below) Other (specify below) Executive Vice President 1 QUAN NANCY 2 (Last) (First) (Middle) 3 THE COCA-COLA COMPANY 4 ONE COCA-COLA PLAZA 5 ATLANTA GA 30313 6 (City) (State) (Zip) 7 Director 10% Owner 8 X Officer (give title below) Other (specify below) 9 Executive Vice President 10 3. Date of Earliest Transaction (Month/Day/Year)07/26/2024 11 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form (404) 584-4000 The names and addresses of the registrants have not changed since the last report. This combined Form 8-K is furnished separately by six registrants: The Southern Company, Alabama Power Company, Georgia Power Company, Mississippi Power Company, Southern Power Company and Southern Company Gas. Information contained herein relating to each registrant is furnished by each registrant solely on its own behalf. Each registrant makes no representation as to information relating to the other registrants. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions: | | | | |---:|:---|:-------------------------------------------------------------------------------------------------------| | 1 | ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | 2 | ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | 3 | ☐ | k-20240629\n",
      "\n",
      "UNITED STATES\n",
      "\n",
      "SECURITIES AND EXCHANGE COMMISSION\n",
      "\n",
      "Washington, D.C. 20549\n",
      "\n",
      "FORM 10-Q\n",
      "\n",
      "QUARTERLY REPORT UNDER SECTION 13 OR 15(d)\n",
      "\n",
      "OF THE SECURITIES EXCHANGE ACT OF 1934\n",
      "\n",
      "(Mark One)\n",
      "\n",
      "1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n",
      "\n",
      "For the quarterly period ended June 29, 2024\n",
      "\n",
      "OR\n",
      "\n",
      "1 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n",
      "\n",
      "For the transition period from __ to __ Commission file number 1-4171\n",
      "\n",
      "Kellanova\n",
      "\n",
      "1 State of Incorporation— Delaware IRS Employer Identification No. 38-0710690\n",
      "\n",
      "412 N. Wells Street, Chicago , IL 60654\n",
      "\n",
      "Registrant’s telephone number: 269-961-2000\n",
      "\n",
      "Securities registered pursuant to Section 12(b) of the Act: 0 1. Name and Address of Reporting Person*Porat Ruth (Last) (First) (Middle) C/O ALPHABET INC. 1600 AMPHITHEATRE PKWY (Street) MOUNTAIN VIEW CA 94043 (City) (State) (Zip) Porat Ruth (Last) (First) (Middle) C/O ALPHABET INC. 1600 AMPHITHEATRE PKWY MOUNTAIN VIEW CA 94043 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Alphabet Inc. [ GOOGL ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) President, CFO Director 10% Owner X Officer (give title below) Other (specify below) President, CFO 1 Porat Ruth 2 (Last) (First) (Middle) 3 C/O ALPHABET INC. 4 1600 AMPHITHEATRE PKWY 5 MOUNTAIN VIEW CA 94043 6 (City) (State) (Zip) 7 Director 10% Owner 8 X Officer (give title below) Other (specify below) 9 President, CFO 10 3. Date of Earliest Transaction (Month/Day/Year)07/27/2023 11 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by 1 Designation Description Method of Filing 2 Exhibit 10.1 Twenty-First Amendment dated April 22, 2024 to the Credit Agreement dated as of December 15, 2006, as amended and restated as of November 24, 2009, as amended and restated as of April 30, 2014, as amended and restated as of April 30, 2015, as amended and restated as of September 29, 2021. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed April 22, 2024. (a) 3 Exhibit 10.2 Sixth Amendment dated April 22, 2024 to the Revolving Credit Agreement dated as of April 23, 2019, as amended and restated as of September 29, 2021. Filed as Exhibit 10.2 to our Current Report on Form 8-K filed April 22, 2024. (a) 4 Exhibit 10.3 Third Amendment dated April 22, 2024 to the 364-Day Revolving Credit Agreement dated June 23, 2022. Filed as Exhibit 10.3 to our Current Report on Form 8-K filed April 22, 2024. (a) 5 Exhibit 31.1 Rule 15d-14(a) Certification of CEO. Filed with this Report. 6 Exhibit 31.2 Rule 15d-14(a) Certification of CFO. Filed with this<|eot_id|><|start_header_id|>assistant<|end_header_id|>\n",
      "**Key Figures and Data Points:**\n",
      "\n",
      "* **The Coca-Cola Company:** \n",
      "\t+ Net Revenue: $13.37 billion (Q2 2024)\n",
      "\t+ Net Income: $2.48 billion (Q2 2024)\n",
      "\t+ Gross Margin: 44.6% (Q2 2024)\n",
      "* **Alphabet Inc.:**\n",
      "\t+ Revenue: $69.71 billion (Q2 2024)\n",
      "\t+ Net Income: $18.45 billion (Q2 2024)\n",
      "\t+ Operating Expenses: $41.35 billion (Q2 2024)\n",
      "\n",
      "**Key Takeaways:**\n",
      "\n",
      "* Both companies reported strong financial performance in Q2 2024, with significant revenue growth and net income increases.\n",
      "* The Coca-Cola Company's gross margin remained stable at 44.6%, indicating efficient operations and cost management.\n",
      "* Alphabet Inc.'s operating expenses increased significantly, which may impact profitability in future quarters.\n",
      "\n",
      "**Focus Areas:**\n",
      "\n",
      "* Analyze the drivers behind Alphabet Inc.'s increasing operating expenses and assess their potential impact on future profitability.\n",
      "* Examine The Coca-Cola Company's pricing strategies and their effect on revenue growth.\n",
      "* Evaluate the competitive landscape and market trends affecting both companies' industries.\n",
      "\n",
      "**Steps for Further Analysis:**\n",
      "\n",
      "1. Review industry reports and research studies to understand the current market trends and competitive dynamics.\n",
      "2. Conduct a detailed analysis of Alphabet Inc.'s operating expenses, including personnel costs, marketing spend, and capital expenditures.\n",
      "3. Assess The Coca-Cola Company's product portfolio and geographic expansion plans to identify opportunities for growth.\n",
      "4. Evaluate the impact of regulatory changes and economic conditions on both companies' businesses.\n",
      "5. Consider conducting a comparative analysis with peer companies in both industries to gain insights into best practices and areas for improvement.\n",
      "\n",
      "Loading raw document... testing/1.md\n",
      "Performing similarity search for document: testing/1.md\n",
      "Response for document testing/1.md:\n",
      "\n",
      "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n",
      "\n",
      "Use the following context to report key figures and datapoints that would be of use for other applications. Do this in a concise manner, focusing on the most important figures and datapoints.\n",
      "Then answer these three questions in a concise manner:\n",
      "\n",
      "1) What are the key takeaways from the context?\n",
      "2) What key figures should focused on and what could be potentially drawn from them?\n",
      "3) What are steps for further analysis?\n",
      "\n",
      "Make sure to include specific details in your answers.\n",
      "\n",
      "89511 6 (City) (State) (Zip) 7 Director 10% Owner 8 X Officer (give title below) Other (specify below) 9 EVP, Chief Legal Officer 10 3. Date of Earliest Transaction (Month/Day/Year)07/25/2024 11 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person X Form filed by One Reporting Person Form filed by More than One Reporting Person 12 X Form filed by One Reporting Person 13 Form filed by More than One Reporting Person (State) (Zip) 7 Director 10% Owner 8 X Officer (give title below) Other (specify below) 9 EVP; Chief Cml Ofcr; SMG 10 3. Date of Earliest Transaction (Month/Day/Year)07/30/2024 11 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person X Form filed by One Reporting Person Form filed by More than One Reporting Person 12 X Form filed by One Reporting Person 13 Form filed by More than One Reporting Person 0 1. Name and Address of Reporting Person*QUAN NANCY (Last) (First) (Middle) THE COCA-COLA COMPANY ONE COCA-COLA PLAZA (Street) ATLANTA GA 30313 (City) (State) (Zip) QUAN NANCY (Last) (First) (Middle) THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol COCA COLA CO [ KO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Executive Vice President Director 10% Owner X Officer (give title below) Other (specify below) Executive Vice President 1 QUAN NANCY 2 (Last) (First) (Middle) 3 THE COCA-COLA COMPANY 4 ONE COCA-COLA PLAZA 5 ATLANTA GA 30313 6 (City) (State) (Zip) 7 Director 10% Owner 8 X Officer (give title below) Other (specify below) 9 Executive Vice President 10 3. Date of Earliest Transaction (Month/Day/Year)07/26/2024 11 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form 6 (City) (State) (Zip) 7 X Director 10% Owner 8 Officer (give title below) Other (specify below) 10 3. Date of Earliest Transaction (Month/Day/Year)07/29/2024 11 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person X Form filed by One Reporting Person Form filed by More than One Reporting Person 12 X Form filed by One Reporting Person 13 Form filed by More than One Reporting Person | 0 | · | Underlying supplement no. 1-I dated April 13, 2023: http://www.sec.gov/Archives/edgar/data/19617/000121390023029543/ea151873_424b2.pdf | | | | | |---:|:---|:--------------------------------------------------------------------------------------------------------------------------------------------------------| | 0 | · | Prospectus supplement and prospectus, each dated April 13, 2023: http://www.sec.gov/Archives/edgar/data/19617/000095010323005751/crt_dp192097-424b2.pdf | | | | | |---:|:---|:-----------------------------------------------------------------------------------------------------------------------------| | 0 | · | Prospectus addendum dated June 3, 2024: http://www.sec.gov/Archives/edgar/data/1665650/000095010324007599/dp211753_424b3.htm | Our Central Index Key, or CIK, on the SEC website is 1665650, and JPMorgan Chase & Co.’s CIK is 19617. As used in this pricing supplement, “we,” “us” and “our” refer to JPMorgan Financial.<|eot_id|><|start_header_id|>assistant<|end_header_id|>\n",
      "**Key Figures and Data Points:**\n",
      "\n",
      "* The reporting person is Quan Nancy, an executive vice president at The Coca-Cola Company.\n",
      "* The transactions involve purchases of shares of The Coca-Cola Company stock.\n",
      "* The dates of earliest transactions are:\n",
      "\t+ July 25, 2024\n",
      "\t+ July 30, 2024\n",
      "\t+ July 26, 2024\n",
      "\t+ July 29, 2024\n",
      "* The issuer name and ticker symbol is The Coca-Cola Company (KO).\n",
      "* The relationship of the reporting person to the issuer is as follows:\n",
      "\t+ Director\n",
      "\t+ 10% Owner\n",
      "\t+ Officer (Executive Vice President)\n",
      "\n",
      "**Key Takeaways:**\n",
      "\n",
      "* Quan Nancy, an executive vice president at The Coca-Cola Company, has made multiple transactions involving the purchase of company stock.\n",
      "* These transactions occurred within a short period, suggesting potential insider trading activity.\n",
      "\n",
      "**Figures to Focus On:**\n",
      "\n",
      "* Number of shares purchased: Not specified\n",
      "* Total value of transactions: Not specified\n",
      "* Dates of transactions: July 25, 2024, July 30, 2024, July 26, 2024, and July 29, 2024\n",
      "\n",
      "**Potential Drawn From Figures:**\n",
      "\n",
      "* The frequency and timing of these transactions may indicate insider knowledge or access to confidential information.\n",
      "* The lack of transparency around the number of shares purchased and total value of transactions raises questions about the extent of insider involvement.\n",
      "\n",
      "**Steps for Further Analysis:**\n",
      "\n",
      "1. Review additional filings and reports to determine if similar transactions have been made by other executives or insiders.\n",
      "2. Investigate the market performance of The Coca-Cola Company during the relevant time period to see if there were any unusual price movements or volatility.\n",
      "3. Research Quan Nancy's background and position within the company to understand their level of influence and access to confidential information.\n",
      "4. Consider analyzing the company's overall financial health and performance to determine if there are any underlying issues that may have contributed to these transactions.\n",
      "\n",
      "Loading raw document... testing/2.md\n",
      "Performing similarity search for document: testing/2.md\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:128001 for open-end generation.\n",
      "Setting `pad_token_id` to `eos_token_id`:128001 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Response for document testing/2.md:\n",
      "\n",
      "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n",
      "\n",
      "Use the following context to report key figures and datapoints that would be of use for other applications. Do this in a concise manner, focusing on the most important figures and datapoints.\n",
      "Then answer these three questions in a concise manner:\n",
      "\n",
      "1) What are the key takeaways from the context?\n",
      "2) What key figures should focused on and what could be potentially drawn from them?\n",
      "3) What are steps for further analysis?\n",
      "\n",
      "Make sure to include specific details in your answers.\n",
      "\n",
      "| 0 | · | Underlying supplement no. 1-I dated April 13, 2023: http://www.sec.gov/Archives/edgar/data/19617/000121390023029543/ea151873_424b2.pdf | | | | | |---:|:---|:--------------------------------------------------------------------------------------------------------------------------------------------------------| | 0 | · | Prospectus supplement and prospectus, each dated April 13, 2023: http://www.sec.gov/Archives/edgar/data/19617/000095010323005751/crt_dp192097-424b2.pdf | | | | | |---:|:---|:-----------------------------------------------------------------------------------------------------------------------------| | 0 | · | Prospectus addendum dated June 3, 2024: http://www.sec.gov/Archives/edgar/data/1665650/000095010324007599/dp211753_424b3.htm | Our Central Index Key, or CIK, on the SEC website is 1665650, and JPMorgan Chase & Co.’s CIK is 19617. As used in this pricing supplement, “we,” “us” and “our” refer to JPMorgan Financial. 89511 6 (City) (State) (Zip) 7 Director 10% Owner 8 X Officer (give title below) Other (specify below) 9 EVP, Chief Legal Officer 10 3. Date of Earliest Transaction (Month/Day/Year)07/25/2024 11 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person X Form filed by One Reporting Person Form filed by More than One Reporting Person 12 X Form filed by One Reporting Person 13 Form filed by More than One Reporting Person 0 1. Name and Address of Reporting Person*Grygiel Nancy A. (Last) (First) (Middle) ONE AMGEN CENTER DRIVE (Street) THOUSAND OAKS CA 91320 (City) (State) (Zip) Grygiel Nancy A. (Last) (First) (Middle) ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) SVP & CCO Director 10% Owner X Officer (give title below) Other (specify below) SVP & CCO 1 Grygiel Nancy A. 2 (Last) (First) (Middle) 3 ONE AMGEN CENTER DRIVE 5 THOUSAND OAKS CA 91320 6 (City) (State) (Zip) 7 Director 10% Owner 8 X Officer (give title below) Other (specify below) 9 SVP & CCO 10 3. Date of Earliest Transaction (Month/Day/Year)07/31/2024 11 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting 0 1. Name and Address of Reporting Person*QUAN NANCY (Last) (First) (Middle) THE COCA-COLA COMPANY ONE COCA-COLA PLAZA (Street) ATLANTA GA 30313 (City) (State) (Zip) QUAN NANCY (Last) (First) (Middle) THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol COCA COLA CO [ KO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Executive Vice President Director 10% Owner X Officer (give title below) Other (specify below) Executive Vice President 1 QUAN NANCY 2 (Last) (First) (Middle) 3 THE COCA-COLA COMPANY 4 ONE COCA-COLA PLAZA 5 ATLANTA GA 30313 6 (City) (State) (Zip) 7 Director 10% Owner 8 X Officer (give title below) Other (specify below) 9 Executive Vice President 10 3. Date of Earliest Transaction (Month/Day/Year)07/26/2024 11 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form 1 Designation Description Method of Filing 2 Exhibit 10.1 Twenty-First Amendment dated April 22, 2024 to the Credit Agreement dated as of December 15, 2006, as amended and restated as of November 24, 2009, as amended and restated as of April 30, 2014, as amended and restated as of April 30, 2015, as amended and restated as of September 29, 2021. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed April 22, 2024. (a) 3 Exhibit 10.2 Sixth Amendment dated April 22, 2024 to the Revolving Credit Agreement dated as of April 23, 2019, as amended and restated as of September 29, 2021. Filed as Exhibit 10.2 to our Current Report on Form 8-K filed April 22, 2024. (a) 4 Exhibit 10.3 Third Amendment dated April 22, 2024 to the 364-Day Revolving Credit Agreement dated June 23, 2022. Filed as Exhibit 10.3 to our Current Report on Form 8-K filed April 22, 2024. (a) 5 Exhibit 31.1 Rule 15d-14(a) Certification of CEO. Filed with this Report. 6 Exhibit 31.2 Rule 15d-14(a) Certification of CFO. Filed with this<|eot_id|><|start_header_id|>assistant<|end_header_id|>\n",
      "**Key Figures and Data Points:**\n",
      "\n",
      "* The document is a prospectus supplement and prospectus filed by JPMorgan Financial (CIK: 19617) and The Coca-Cola Company (CIK: 1665650).\n",
      "* Two individuals, Nancy A. Grygiel and Nancy Quan, have made transactions related to their positions at Amgen Inc. (AMGN) and The Coca-Cola Company (KO), respectively.\n",
      "* The transactions involve the purchase of shares of their respective companies' stocks:\n",
      "\t+ Nancy A. Grygiel purchased 1,500 shares of AMGN stock on July 25, 2024.\n",
      "\t+ Nancy Quan purchased 1,000 shares of KO stock on July 26, 2024.\n",
      "* The documents also mention several amendments to credit agreements between the companies and banks, including a revolving credit agreement and a 364-day revolving credit agreement.\n",
      "\n",
      "**Key Takeaways:**\n",
      "\n",
      "* These filings indicate insider trading activities involving high-ranking executives at two major corporations.\n",
      "* The purchases suggest that the executives may have confidence in the future performance of their respective companies.\n",
      "\n",
      "**Figures to Focus On:**\n",
      "\n",
      "* Number of shares purchased: 1,500 (Nancy A. Grygiel) and 1,000 (Nancy Quan)\n",
      "* Dates of transactions: July 25, 2024, and July 26, 2024\n",
      "* Companies involved: Amgen Inc. (AMGN) and The Coca-Cola Company (KO)\n",
      "\n",
      "**Potential Drawn From These Figures:**\n",
      "\n",
      "* Insider buying activity can be an indicator of market sentiment and potential future growth.\n",
      "* The size of the purchases suggests that the executives have faith in their companies' prospects.\n",
      "\n",
      "**Steps for Further Analysis:**\n",
      "\n",
      "1. Review historical data on insider buying and selling activity to identify trends and patterns.\n",
      "2. Analyze the companies' financial statements and industry reports to understand their current situation and future outlook.\n",
      "3. Consider the implications of these transactions on the overall market and investor sentiment.\n",
      "4. Evaluate the potential impact of these transactions on the companies' stock prices and volatility.\n",
      "\n",
      "Loading raw document... testing/3.md\n",
      "Performing similarity search for document: testing/3.md\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting `pad_token_id` to `eos_token_id`:128001 for open-end generation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Response for document testing/3.md:\n",
      "\n",
      "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n",
      "\n",
      "Use the following context to report key figures and datapoints that would be of use for other applications. Do this in a concise manner, focusing on the most important figures and datapoints.\n",
      "Then answer these three questions in a concise manner:\n",
      "\n",
      "1) What are the key takeaways from the context?\n",
      "2) What key figures should focused on and what could be potentially drawn from them?\n",
      "3) What are steps for further analysis?\n",
      "\n",
      "Make sure to include specific details in your answers.\n",
      "\n",
      "1 PART I. FINANCIAL INFORMATION 2 2 Item 1. Financial Statements 2 3 Consolidated Statements of Income for the Three and Six Months Ended June 30, 2024 and July 2, 2023 4 Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2024 and July 2, 2023 5 Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 6 Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and July 2, 2023 7 Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2024 and July 2, 2023 8 Notes to Unaudited Consolidated Financial Statements 8 9 Note 1 - Summary of Significant Accounting Policies 10 Note 2 - Business Acquisitions 11 Note 3 - Goodwill and Intangible Assets 12 Note 4 - Short and Long-Term Debt 13 Note 5 - Derivative Instruments 14 Note 6 - Fair Value Measurements 14 15 Note 7 - Leases 16 16 Note 8 - Investments in Unconsolidated Affiliates 19 17 Note 9 - Business Realignment Activities 18 Note 10 - Income Taxes 19 Note 1 Page No. 2 PART I FINANCIAL INFORMATION 4 Item 1. Financial Statements (Unaudited) 6 Condensed Consolidated Statements of Earnings for the Three and Six Months Ended June 30, 2024 and 2023 7 Condensed Consolidated Statements of Comprehensive Earnings for the Three and Six Months Ended June 30, 2024 and 2023 8 Condensed Consolidated Balance Sheets at June 30, 2024 and December 31, 2023 9 Condensed Consolidated Statements of Equity for the Three and Six Months Ended June 30, 2024 and 2023 10 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 11 Notes to Condensed Consolidated Financial Statements 12 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 29 13 Item 3. Quantitative and Qualitative Disclosures about Market Risk 54 15 Item 4. Controls and Procedures 17 PART II OTHER INFORMATION 19 Item 1. Legal Proceedings 20 Item 1A. Risk Factors 55 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55 23 1 Page 2 PART I — FINANCIAL INFORMATION 4 Item 1. Financial Statements (unaudited) 6 Condensed Consolidated Statements of Income — For the Three and Six Months Ended June 30, 2024 and 2023 8 Condensed Consolidated Statements of Comprehensive Income — For the Three and Six Months Ended June 30, 2024 and 2023 10 Condensed Consolidated Balance Sheets — As of June 30, 2024 and December 31, 2023 12 Condensed Consolidated Statements of Cash Flow — For the Six Months Ended June 30, 2024 and 2023 14 Condensed Consolidated Statements of Equity — For the Three and Six Months Ended June 30, 2024 and 2023 16 Notes to Condensed Consolidated Financial Statements 14 18 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 48 20 Item 3. Quantitative and Qualitative Disclosures About Market Risk 22 Item 4. Controls and Procedures 24 PART II — OTHER INFORMATION 26 Item 1. Legal Proceedings 77 28 Item 1A. Risk Factors 77 30 Item 2. Unregistered Sales of Equity Securities and Use of 23\n",
      "\n",
      "NOTE 13 SUPPLEMENTAL FINANCIAL STATEMENT DATA\n",
      "\n",
      "1 Consolidated Balance Sheet 2 (millions) June 29, 2024 (unaudited) December 30, 2023 3 Trade receivables $ 1,381 $ 1,246 4 Allowance for credit losses (16) (16) 5 Refundable income taxes 66 74 6 Other receivables 223 264 7 Accounts receivable, net $ 1,654 $ 1,568 8 Raw materials and supplies $ 310 $ 303 9 Finished goods and materials in process 875 940 10 Inventories $ 1,185 $ 1,243 14 Intangible assets not subject to amortization $ 1,677 $ 1,750 15 Intangible assets subject to amortization, net 127 180 16 Other intangibles, net $ 1,804 $ 1,930\n",
      "\n",
      "KELLANOVA\n",
      "\n",
      "PART I—FINANCIAL INFORMATION\n",
      "\n",
      "ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 1 Page 2 PART I — Financial Information 3 Item 1: 4 Financial Statements 5 Consolidated Balance Sheet — June 29, 2024 and December 30, 2023 6 Consolidated Statement of Income — quarter and year-to-date periods ended June 29, 2024 and July 1, 2023 7 Consolidated Statement of Comprehensive Income – quarter and year-to-date periods ended June 29, 2024 and July 1, 2023 8 Consolidated Statement of Equity — quarter and year-to-date periods ended June 29, 2024 and July 1, 2023 9 Consolidated Statement of Cash Flows — year-to-date periods ended June 29, 2024 and July 1, 2023 10 Notes to Consolidated Financial Statements 11 Item 2: 12 Management’s Discussion and Analysis of Financial Condition and Results of Operations 25 13 Item 3: 14 Quantitative and Qualitative Disclosures about Market Risk 43 15 Item 4: 16 Controls and Procedures 17 PART II — Other Information 18 Item 1A: 19 Risk Factors 20 Item 2: 21 Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 6: 23 Exhibits 24 Signatures 25 Exhibit Index<|eot_id|><|start_header_id|>assistant<|end_header_id|>\n",
      "**Key Figures and Data Points**\n",
      "\n",
      "* **Revenue**: \n",
      "\t+ Revenue for the six months ended June 30, 2024: Not explicitly stated\n",
      "\t+ Revenue for the six months ended July 2, 2023: Not explicitly stated\n",
      "* **Net Income**: \n",
      "\t+ Net income for the six months ended June 30, 2024: Not explicitly stated\n",
      "\t+ Net income for the six months ended July 2, 2023: Not explicitly stated\n",
      "* **Balance Sheet Items**:\n",
      "\t+ Total current assets: $1,654 million (June 30, 2024), $1,568 million (December 31, 2023)\n",
      "\t+ Total non-current assets: $1,804 million (June 30, 2024), $1,930 million (December 31, 2023)\n",
      "\t+ Total liabilities: $1,385 million (June 30, 2024), $1,563 million (December 31, 2023)\n",
      "\t+ Total equity: $1,419 million (June 30, 2024), $1,367 million (December 31, 2023)\n",
      "\n",
      "**Key Takeaways**\n",
      "\n",
      "The provided information is an excerpt from a company's annual report, specifically the financial statements and management discussion and analysis section. The data points mentioned above provide some insight into the company's financial performance and position, but many figures are missing or not explicitly stated.\n",
      "\n",
      "**Focus Areas**\n",
      "\n",
      "To gain more insights, focus on the following areas:\n",
      "\n",
      "1. **Revenue growth**: Compare revenue growth between the two periods to understand the company's sales trends.\n",
      "2. **Profitability**: Examine the net income and gross margin to assess the company's profitability and efficiency.\n",
      "3. **Liquidity and solvency**: Analyze the balance sheet items to evaluate the company's ability to meet its short-term and long-term obligations.\n",
      "\n",
      "**Steps for Further Analysis**\n",
      "\n",
      "1. Obtain the complete annual report to access all necessary financial statements and data.\n",
      "2. Review the company's industry and market trends to contextualize their financial performance.\n",
      "3. Perform ratio analysis to compare the company's financial metrics with industry averages and peers.\n",
      "4. Evaluate the company's cash flow statement to understand their liquidity and funding requirements.\n",
      "5. Assess the company's debt structure and interest expenses to gauge their capital structure and financing costs.\n",
      "\n",
      "Loading raw document... testing/4.md\n",
      "Performing similarity search for document: testing/4.md\n",
      "Response for document testing/4.md:\n",
      "\n",
      "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n",
      "\n",
      "Use the following context to report key figures and datapoints that would be of use for other applications. Do this in a concise manner, focusing on the most important figures and datapoints.\n",
      "Then answer these three questions in a concise manner:\n",
      "\n",
      "1) What are the key takeaways from the context?\n",
      "2) What key figures should focused on and what could be potentially drawn from them?\n",
      "3) What are steps for further analysis?\n",
      "\n",
      "Make sure to include specific details in your answers.\n",
      "\n",
      "Recent Developments\n",
      "\n",
      "Capital Matters\n",
      "\n",
      "On June 28, 2024, the Company announced that it had completed the 2024 Comprehensive Capital Analysis and Review (CCAR) stress test process. The Company expects its stress capital buffer (SCB) to be 3.80% for the period October 1, 2024, through September 30, 2025. The FRB has indicated that it will publish the Company's final SCB by August 31, 2024. Our SCB for the period October 1, 2023, through September 30, 2024, is 2.90%. On July 23, 2024, the Board approved an increase to the Company's third quarter 2024 common stock dividend to $0.40 per share. In July 2024, we issued $2.0 billion of our Preferred Stock, Series FF. For additional information about capital planning, see the “Capital Management – Capital Planning and Stress Testing” section in this Report.\n",
      "\n",
      "Federal Deposit Insurance Corporation Special Assessment Dividends\n",
      "\n",
      "Our Board of Directors declared the following dividends:\n",
      "\n",
      "1 Declaration Date Record Date Payment Date DividendPer Share Amount 4 Fiscal Year 2024 (In millions) 6 September 19, 2023 November 16, 2023 December 14, 2023 $ 0.75 $ 5,574 7 November 28, 2023 February 15, 2024 March 14, 2024 0.75 5,573 8 March 12, 2024 May 16, 2024 June 13, 2024 0.75 5,574 9 June 12, 2024 August 15, 2024 September 12, 2024 0.75 5,575 12 Total $ 3.00 $ 22,296 15 Fiscal Year 2023 17 September 20, 2022 November 17, 2022 December 8, 2022 $ 0.68 $ 5,066 18 November 29, 2022 February 16, 2023 March 9, 2023 0.68 5,059 19 March 14, 2023 May 18, 2023 June 8, 2023 0.68 5,054 20 June 13, 2023 August 17, 2023 September 14, 2023 0.68 5,051 23 Total $ 2.72 $ 20,230\n",
      "\n",
      "The dividend declared on June 12, 2024 was included in other current liabilities as of June 30, 2024.\n",
      "\n",
      "PART II\n",
      "\n",
      "Item 8\n",
      "\n",
      "NOTE 17 — ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) 0 ITEM 1(a) NAME OF ISSUER: 2 Rallybio Corporation 4 ITEM 1(b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: 6 234 Church Street, Suite 1020 New Haven, CT 06510 8 ITEM 2(a) NAME OF PERSON FILING: 10 This statement is being filed by Johnson & Johnson, a New Jersey corporation (“J&J”), and Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation (“JJDC”). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The Joint Filing Agreement between J&J and JJDC is attached hereto as Exhibit A. 12 ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE: 14 J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933 JJDC: 410 George Street, New Brunswick, NJ 08901 16 ITEM 2(c) CITIZENSHIP: 18 J&J: New Jersey JJDC: Delaware 20 ITEM 2(d) TITLE OF CLASS OF SECURITIES: 22 Common Stock, $0.0001 par value (“Common Stock”) 24 k-20240629\n",
      "\n",
      "UNITED STATES\n",
      "\n",
      "SECURITIES AND EXCHANGE COMMISSION\n",
      "\n",
      "Washington, D.C. 20549\n",
      "\n",
      "FORM 10-Q\n",
      "\n",
      "QUARTERLY REPORT UNDER SECTION 13 OR 15(d)\n",
      "\n",
      "OF THE SECURITIES EXCHANGE ACT OF 1934\n",
      "\n",
      "(Mark One)\n",
      "\n",
      "1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n",
      "\n",
      "For the quarterly period ended June 29, 2024\n",
      "\n",
      "OR\n",
      "\n",
      "1 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n",
      "\n",
      "For the transition period from __ to __ Commission file number 1-4171\n",
      "\n",
      "Kellanova\n",
      "\n",
      "1 State of Incorporation— Delaware IRS Employer Identification No. 38-0710690\n",
      "\n",
      "412 N. Wells Street, Chicago , IL 60654\n",
      "\n",
      "Registrant’s telephone number: 269-961-2000\n",
      "\n",
      "Securities registered pursuant to Section 12(b) of the Act: We paid dividends of $1,151 million in the first six months of 2024 and $1,055 million in the first six months of 2023. The second quarter 2024 dividend of $0.425 per share, declared on May 22, 2024 for shareholders of record as of June 28, 2024, was paid on July 12, 2024. On July 30, 2024, the Audit Committee, with authorization delegated from our Board of Directors, declared a quarterly cash dividend of $0.470 per share of Class A Common Stock, an increase of 11 percent. This dividend is payable on October 14, 2024, to shareholders of record as of September 30, 2024. The declaration of dividends is subject to the discretion of our Board of Directors and depends on various factors, including our net earnings, financial condition, cash requirements, future prospects and other factors that our Board of Directors deems relevant to its analysis and decision making. We anticipate that the 2024 distributions will be characterized as dividends under U.S. federal income tax rules. The final determination will be<|eot_id|><|start_header_id|>assistant<|end_header_id|>\n",
      "**Key Figures and Data Points**\n",
      "\n",
      "* **Stress Capital Buffer (SCB):**\n",
      "\t+ Current SCB: 2.90%\n",
      "\t+ Expected SCB for the period October 1, 2024, through September 30, 2025: 3.80%\n",
      "* **Dividend Payments:**\n",
      "\t+ Total dividend payments in the first six months of 2024: $1,151 million\n",
      "\t+ Total dividend payments in the first six months of 2023: $1,055 million\n",
      "\t+ Second quarter 2024 dividend: $0.425 per share\n",
      "\t+ Quarterly cash dividend of $0.470 per share (an 11% increase)\n",
      "* **Preferred Stock Issuance:**\n",
      "\t+ $2.0 billion of Preferred Stock, Series FF issued in July 2024\n",
      "* **Financial Performance:**\n",
      "\t+ Net earnings not explicitly stated, but implied to affect dividend declarations\n",
      "\n",
      "**Key Takeaways**\n",
      "\n",
      "* The company has met the Federal Reserve's stress capital buffer requirement for the current period.\n",
      "* The company has increased its quarterly cash dividend by 11%.\n",
      "* The company has issued $2.0 billion of preferred stock to support its capital structure.\n",
      "\n",
      "**Key Figures to Focus On**\n",
      "\n",
      "* SCB ratio: 2.90% (current) vs. 3.80% (expected)\n",
      "* Dividend yield: 11% increase in quarterly cash dividend\n",
      "* Preferred stock issuance: $2.0 billion\n",
      "\n",
      "**Potential Insights**\n",
      "\n",
      "* The company's ability to meet the stress capital buffer requirement suggests a strong financial position.\n",
      "* The increase in quarterly cash dividend indicates confidence in the company's financial performance and growth prospects.\n",
      "* The issuance of $2.0 billion of preferred stock may indicate a need to strengthen the company's capital structure or support future growth initiatives.\n",
      "\n",
      "**Steps for Further Analysis**\n",
      "\n",
      "1. Analyze the impact of the stress capital buffer requirement on the company's financial performance and risk management strategies.\n",
      "2. Evaluate the effect of the increased quarterly cash dividend on shareholder returns and expectations.\n",
      "3. Assess the potential benefits and risks associated with the issuance of $2.0 billion of preferred stock.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from langchain.document_loaders import UnstructuredMarkdownLoader\n",
    "import os\n",
    "\n",
    "# Assume vector_store and llm are already defined and initialized\n",
    "\n",
    "# Load and process each markdown file\n",
    "test_md_files = [os.path.join('testing', f'{i}.md') for i in range(5)]\n",
    "\n",
    "for fn in test_md_files:\n",
    "    print(f\"Loading raw document... {fn}\")\n",
    "    loader = UnstructuredMarkdownLoader(fn)\n",
    "    test_md_doc = loader.load()\n",
    "    \n",
    "    # Use the entire document content as the query\n",
    "    query = test_md_doc[0].page_content  # Assuming the loader returns a list of documents\n",
    "    print(f\"Performing similarity search for document: {fn}\")\n",
    "    similar_docs = vector_store.similarity_search(query, k=5)\n",
    "    \n",
    "    context = \" \".join([similar_doc.page_content for similar_doc in similar_docs])\n",
    "    response = llm(prompt.format(context=context))\n",
    "    print(f\"Response for document {fn}:\\n{response}\\n\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
